Blockchain Registration Transaction Record

Sigyn's CardioDialysis Aims to Transform Heart Disease Treatment Using Dialysis Tech

Sigyn Therapeutics unveils CardioDialysis, a breakthrough device using dialysis infrastructure to treat cardiovascular disease with potential 75-95% MACE reduction in ESRD patients.

This development matters because cardiovascular disease remains the world's leading cause of death, and current treatments have significant limitations. Statin drugs, while widely used, only reduce major cardiovascular events by about 25%, leaving substantial room for improvement. The dialysis patient population represents a particularly vulnerable group where cardiovascular mortality is exceptionally high and existing medications have shown limited effectiveness. By leveraging existing dialysis infrastructure that's already widely available, CardioDialysis could potentially bring advanced blood purification therapy to millions of patients who currently lack access to specialized apheresis centers. If successful, this technology could not only extend and improve lives but also create a new treatment paradigm where cardiovascular care becomes integrated with existing renal care systems, potentially making advanced therapy more accessible and affordable for broader populations.